glp·helper
glphelper.com/zepbound/georgia/atlanta
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Atlanta, GA

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Atlanta, GA from the federal NPI registry. Ask each office whether it prescribes Zepbound.[9]

average Zepbound weight loss →trial-anchored estimate
city providers
41
as of today

Same molecule (tirzepatide): Tirzepatide in Atlanta, Mounjaro in Atlanta

Other GLP-1 medicines: Ozempic in Atlanta, Wegovy in Atlanta, Semaglutide in Atlanta

§ 02Provider directory: Georgia
41 of 41 shown

Find a Zepbound provider in Atlanta.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Zepbound by Georgia town, physicians per town
§ 03Getting Zepbound in Atlanta
41 providers · Atlanta, GA

How to get Zepbound in Atlanta.

41 GLP-1 prescribers and 7 local resource types are on record for Atlanta, plus 3 nearby towns in the directory.

Physicians in Atlanta
41 physicians
41 physicians from the federal NPI registry in Atlanta, most listed as Family Medicine (16), Internal Medicine, Endocrinology, Diabetes & Metabolism (14) and Internal Medicine (8). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Columbus (23 providers), Augusta (34 providers) and Savannah (32 providers).
Around the prescription in Atlanta
7 listed nearby
6 dietitians, 6 nutritionists, 4 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Atlanta.
Medicaid (weight loss)
Diabetes only
As of April 2026, Georgia Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Georgia’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

Bar chart of Zepbound dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Zepbound comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition) and moderate to severe obstructive sleep apnea in adults with obesity
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Georgia

Diagnosed diabetes reaches 11.5% of adults in Georgia.

of Georgia adults have obesity
35.4%
diagnosed diabetes
11.5%

Age-adjusted estimates for Georgia, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossoral and sublingual GLP-1 options
§ 05Support around Zepbound in Atlanta
4 gyms

The prescription is one part. Here is the rest, in Atlanta.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Atlanta, GA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.3 on Google · 1,221 reviews
2841 Greenbriar Pkwy SW Unit B
Website
LA Fitness
GYM
4.0 on Google · 1,011 reviews
1496 Church St
Website
LA Fitness
GYM
3.6 on Google · 1,005 reviews
3755 Carmia Dr SW Ste 700
Website
Snap Fitness Atlanta (Glenwood Park)
GYM
4.8 on Google · 922 reviews
920 Glenwood Ave SE Suite 102/103
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lina Abuhamdieh, MS, RDN, LD
RD
Registered dietitian
1802 Abbey Ct
Call 678-554-7576NPI 1568033223
Andrea Addington, RD, LD
RD
Registered dietitian
1000 Johnson Fy Rd Ne
Call 404-851-8697NPI 1982390308
Rachel Agnew
RD
Registered dietitian
1000 Johnson Ferry Rd Ne
Call 404-851-6023NPI 1023280450
Alana Ahrens, MS, RD, LD
RD
Registered dietitian
2050 Cloverdale Dr Se
Call 706-224-2888NPI 1639859184
Alene Albritton, MPH, RD, LD
RD
Registered dietitian
2140 Peachtree Rd Nw Ste 232
Call 404-231-4431NPI 1669556403
Karla Aleman, RD, LD
RD
Registered dietitian
80 Jesse Hill Jr Dr Se
Call 404-616-6015NPI 1730403239
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Zepbound side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
25 to 29%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
19 to 23%
mild
More frequent during dose escalation
Vomiting
8 to 13%
mild
Reduced by slower titration
Constipation
11 to 17%
mild
Abdominal pain
9 to 10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Zepbound costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Zepbound monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
LillyDirect self-pay, KwikPen or vial$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Commercial insurance (weight)Often deniedOn-label for obesity but frequently requires prior authorization
Medicare GLP-1 Bridge$50per monthKwikPen only, Jul 1, 2026 to Dec 31, 2027, Part D enrollees who meet weight and health criteria[5]
Manufacturer savings cardas low as $25per monthCommercial insurance with coverage only; eligibility limits apply
Find Zepbound providers in Atlanta

Physicians from the federal NPI registry. Ask each office whether it prescribes Zepbound.

Zepbound in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Zepbound.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Georgia

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]